How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent disease with many potential long-term metabolic and cardiovascular risks if not managed appropriately. Mean platelet volume (MPV) is a marker associated with adverse cardiovascular events. In this study, we aimed to investigate MPV levels under ethinyl estradiol/cyproterone acetate or metformin therapy for the previous 6 months in PCOS. A total of 114 individuals [metformin treatment (n = 18), ethinyl estradiol/cyproterone acetate treatment (n = 29), newly diagnosed PCOS patient with no treatment (n = 35), and control group of eumenorrheic healthy individuals (n = 32)] were included in the current study. Hematologic parameters other than MPV were similar in all groups. The MPV value was significantly higher in the newly diagnosed PCOS patients compared with the other three groups independent of age, BMI, and C-reactive protein level in multiple regression analysis (P < 0.01). The MPV value of control group was comparable to the groups under ethinyl estradiol/cyproterone acetate or metformin therapy (P = 1.0). There was no statistically significant difference in the white blood cell count among the groups. The MPV values were positively correlated with the homeostatic model assessment-insulin resistance and Ferriman-Gallwey Score (P = 0.044, r = 0.261; P = 0.037, r = 0.229, respectively). Ethinyl estradiol/cyproterone acetate and metformin similarly appear to decrease MPV, a marker of cardiovascular risk. Therefore, a possible beneficial effect of ethinyl estradiol/cyproterone acetate and metformin on long-term cardiovascular morbidities in PCOS may be suggested.

The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome

“…Gursoy et al [26] and Kebapcilar et al [28] reported that patients with PCOS had higher MPV levels, compared to controls. In another study performed by Kabil Kucur et al [27], MPV levels were found higher in patients with PCOS, and after the treatment with ethinyl estradiol/cyproterone acetate or metformin, a significant decrease was observed in MPV levels. It could also be speculated that anti-inflammatory effects of these treatment modalities might contribute to the protective effect on cardiovascular diseases in patients with PCOS.…”

“…It is known that larger platelets are metabolically more active and prone to inflammatory cytokine release. It was shown that MPV values are higher in patients with PCOS than controls [26][27][28].…”

Effects of Zinc Supplementation on Markers of Insulin Resistance and Lipid Profiles in Women with Polycystic Ovary Syndrome: a Randomized, Double-blind, Placebo-controlled Trial

“…Polycystic ovary syndrome (PCOS) is a prevalent disease with many potential long-term metabolic disturbances including insulin resistance, dyslipidemia and androgen excess if not managed appropriately 1 2 . The prevalence of metabolic syndrome (MetS) and insulin resistance (IR) among Iranian women diagnosed with different phenotypic subgroups of PCOS based on the Rotterdam criteria were reported 24.9 and 24.3%, respectively 3 .…”

Mean platelet volume and polycystic ovary syndrome: a systematic review and meta-analysis

“…Finally, 10 studies without overlapping patients complied with the inclusion criteria, so were selected for the meta-analysis. 19 – 28 A flowchart illustrating the study selection process is presented in Figure 1 .…”